Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368624 | 0.83 | HMGB1 (0.43) | ALDH1A1ALOX15HMGB1FOLH1 | |
| SCHEMBL1792164 | 0.80 | ALDH1A1 (0.48) | ALDH1A1ALOX15PTPN1FOLH1LMNA | |
| SCHEMBL4777715 | 0.80 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNA | |
| SCHEMBL13622156 | 0.79 | ALDH1A1 (0.39) | ALDH1A1ALOX15PTPN1HMGB1FOLH1 | |
| SCHEMBL6120117 | 0.77 | ALDH1A1 (0.51) | ALDH1A1ALOX15LMNA | |
| SCHEMBL18130159 | 0.75 | GABRA1 (0.36) | ALDH1A1 | |
| SCHEMBL1950873 | 0.75 | ALDH1A1 (0.42) | ALDH1A1ALOX15 | |
| SCHEMBL6367716 | 0.74 | ALDH1A1 (0.45) | ALDH1A1ALOX15PTPN1 | |
| SCHEMBL13622163 | 0.74 | MRGPRX4 (0.41) | ALDH1A1ALOX15PTPN1 | |
| SCHEMBL2186777 | 0.73 | ALDH1A1 (0.39) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | ALDH1A1 2078/4885ALOX15 1871/4885PTPN1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.